ALYREF and hepatocellular carcinoma: Functional assays confirm that ALYREF knockdown suppresses GBC cell malignancy, while its overexpression exacerbates tumorigenic behaviors, mirroring its oncogenic roles in gastric35 and hepatocellular cancers.33